References
Referencesarepublicationsthatsupporttheproducts'biologicalactivity.
Wangetal(2012)InhibitionofmammaliantargetofrapamycinsignalingbyCCI-779(temsirolimus)inducesgrowthinhibitionandcellcyclearrestinCashmeregoatfetalfibroblasts(Caprahircus).DNACellBiol.311095PMID:22320865
DelBufaloetal(2006)AntiangiogenicpotentialoftheMammaliantargetofrapamycininhibitortemsirolimus.CancerRes.665549PMID:16740688
WuLetal(2005)EffectsofthemammaliantargetofrapamycininhibitorCCI-779usedaloneorwithchemotherapyonhumanprostatecancercellsandxenografts.CancerRes.652825PMID:15805283
Lietal(2013)ThenovelmTORinhibitorCCI-779(temsirolimus)inducesantiproliferativeeffectsthroughinhibitionofmTORinBel-7402livercancercells.CancerCellInt.13PMID:23537100
Galluzzietal(2017)Pharmacologicalmodulationofautophagy:therapeuticpotentialandpersistingobstacles.Nat.Rev.Drug.Discov.PMID:28529316
Keywords:Temsirolimus,supplier,Breast,cancer,mTOR,inhibitors,inhibits,rapamycin,kinases,suppresses,cell,tumour,tumor,growth,VEGF,Vascular,endothelial,growth,factor,CCI-779,CCI-779,mTOR,Cell,Cycle,Inhibitors,Autophagy,mTOR,TocrisBioscience